Insulin Glargine vs PACAP-27

Head-to-head comparison of Insulin Glargine (Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog)) and PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyInsulin GlarginePACAP-27
CategoryDiabetes & MetabolicDiabetes & Metabolic
Full NameInsulin glargine (A21Gly,B31Arg,B32Arg human insulin analog)Pituitary Adenylate Cyclase-Activating Polypeptide-27
Molecular Weight6063.6 Da3158 Da
Half-LifeAbout 12-24 hoursminutes
Amino Acids5127
Typical Dose0.1-0.2 U/kg once dailyResearch-only: 0.1-1 nmol/kg
RouteSubcutaneousIntraperitoneal/Subcutaneous
Purity≥98%≥98%
Studies Count13000220
Research StatusApprovedPre-clinical

Insulin Glargine Benefits

  • ✓Once-daily basal coverage
  • ✓Smooth action profile
  • ✓Lower nocturnal hypoglycemia risk
  • ✓Improves fasting glucose control

PACAP-27 Benefits

  • ✓anti-apoptotic signaling
  • ✓insulin secretagogue effect
  • ✓reduced ER stress
  • ✓islet cytoprotection

Insulin Glargine Dosing

Inject SC once daily at the same time each day|Titrate every 3-4 days to fasting glucose targets|Can be combined with prandial insulin

PACAP-27 Dosing

0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing

Insulin Glargine Side Effects

  • ⚠Hypoglycemia
  • ⚠Injection-site reactions
  • ⚠Weight gain

PACAP-27 Side Effects

  • ⚠flushing
  • ⚠hypotension at high exposure
  • ⚠headache

Research Overview

Insulin Glargine

Clinical and translational studies support its use as a basal comparator because of prolonged absorption and stable glycemic control. It is heavily used in basal-bolus regimen research and insulin-delivery optimization studies.

PACAP-27

PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Insulin Glargine stacks with:

Insulin LisproInsulin Aspart

PACAP-27 stacks with:

GLP-1 analogsDPP-4 inhibitorsdiet and exercise
basal insulinlong-actingfasting glucoseneuropeptidebeta-cell protectioncAMP signaling